Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 8Osteosarcoma 3Vomiting 2Neuroectodermal Tumors, Primitive, Peripheral 2Nausea 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Sarcoma, Synovial 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hepatoblastoma 1Fibrosarcoma 1Drug-Related Side Effects and Adverse Reactions 1Dendritic Cell Sarcoma, Interdigitating 1Chemotherapeutic Agent Toxicity 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1

Interventions

apatinib 2Drug Therapy 2Tretinoin 1Radiotherapy 1Pharmaceutical Services 1Nivolumab 1Methylprednisolone 1Ifosfamide 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Drug-Related Side Effects and Adverse Reactions × Ifosfamide × Clear all
NCT04690231 2022-03-15

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Peking University People's Hospital

Phase NA Completed
79 enrolled
Sarcoma

Osteosarcoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡